Page 2 - Small Pharma News Today

Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc.

• Shareholders overwhelmingly vote in favour of Cybin’s acquisition of Small Pharma, supporting the combined company’s vision to build an international...

Short-acting psychedelics biotech Small Pharma Inc.

Short-acting psychedelics biotech Small Pharma Inc. DMTTF has obtained a final order from the Supreme Court of British Columbia approving the announced plan…

Small Pharma Inc. ("Small Pharma"), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions and Cybin Inc. (NEO:CYBN) ("Cybin"), a clinical-stage biopharmaceutical company committed to...

Small Pharma Inc. , a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions and Cybin Inc. , a clinical-stage biopharmaceutical company...

Cybin Inc. , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce...

Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and effica...

Mr. Peter Rands disposed of an aggregate of 1,532,001 common shares in the capital of Small Pharma Inc. (the "Company") between September 25, 2023 and September 27, 2023 at an average price of $0.177 per common share for aggregate proceeds of...

The psychedelic drug market is projected to soar to $7.2 billion by 2029, reflecting a 55% compound annual growth rate (CAGR) and further showing its power.